Wellington Management Group LLP Sells 123,748 Shares of Tempus AI, Inc. $TEM

Key Points

• Wellington Management cut its Tempus AI stake by 24.1% in the second quarter, selling 123,748 shares and retaining 390,241 shares valued at approximately $22.6 million. Institutional investors and hedge funds collectively own 24.22% of the company.
• Tempus AI reported quarterly revenue of $382.5 million, up 21.6% year over year, and an adjusted loss of $0.04 per share that beat analyst expectations. Despite growth, the company posted a negative net margin and analysts expect a full-year loss.
• Analyst sentiment remains broadly favorable, with a consensus “Moderate Buy” rating and an average price target of $68.93 versus the reported share price of $64.62. Recent target changes were mixed, including Piper Sandler’s upgrade to “overweight” and Stifel’s downgrade in its price objective.

Wellington Management Group LLP reduced its position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 24.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 390,241 shares of the company's stock after selling 123,748 shares during the quarter. Wellington Management Group LLP owned about 0.22% of Tempus AI worth $22,607,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in TEM. Eagle Health Investments LP bought a new stake in shares of Tempus AI during the 1st quarter valued at $11,588,000. Alethea Capital Management LLC acquired a new stake in shares of Tempus AI during the fourth quarter worth $1,863,000. Aristotle Atlantic Partners LLC bought a new stake in Tempus AI in the first quarter valued at about $6,179,000. Lingotto Investment Management LLP increased its holdings in Tempus AI by 45.9% in the fourth quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company's stock valued at $67,525,000 after purchasing an additional 359,667 shares during the last quarter. Finally, Wellington Shields Capital Management LLC acquired a new position in Tempus AI in the fourth quarter valued at about $1,393,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Stock Down 0.1%

Shares of Tempus AI stock opened at $64.62 on Friday. The company has a market capitalization of $11.66 billion, a P/E ratio of -44.87 and a beta of 3.72. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The business has a 50-day moving average of $55.77 and a two-hundred day moving average of $52.13. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The business had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.Tempus AI's quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.22) EPS. As a group, equities analysts predict that Tempus AI, Inc. will post -1.38 EPS for the current year.

Insider Transactions at Tempus AI

In other Tempus AI news, CFO James Rogers sold 26,313 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the completion of the transaction, the chief financial officer owned 106,024 shares in the company, valued at approximately $6,361,440. This represents a 19.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 41,095 shares of Tempus AI stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $2,038,722.95. Following the completion of the sale, the chief executive officer directly owned 562,463 shares in the company, valued at approximately $27,903,789.43. This represents a 6.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 1,043,988 shares of company stock worth $56,963,417 in the last 90 days. Company insiders own 24.26% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TEM. Piper Sandler upgraded Tempus AI from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $56.00 to $76.00 in a research report on Tuesday. Needham & Company LLC reissued a "buy" rating and set a $75.00 price objective on shares of Tempus AI in a research note on Friday, July 31st. Stifel Nicolaus decreased their price objective on shares of Tempus AI from $60.00 to $50.00 and set a "hold" rating for the company in a report on Monday, August 3rd. Wall Street Zen raised shares of Tempus AI from a "sell" rating to a "hold" rating in a research note on Saturday, July 25th. Finally, HC Wainwright cut their target price on shares of Tempus AI from $64.00 to $56.00 and set a "buy" rating on the stock in a report on Monday, August 3rd. Eleven research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Tempus AI has a consensus rating of "Moderate Buy" and a consensus target price of $68.93.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source